Skip to main content
Fig. 6 | Cancer Communications

Fig. 6

From: Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

Fig. 6

Survival curves of patients receiving different subsequent treatments. a Curve for T790M+ and T790M− CF patients. b Curve for T790M+ and T790M− BF patients. c Curve for T790M+ and T790M− OF patients. CF, progressive disease limited to the chest in lung/pleural tissues and lymph nodes, with no evidence of progression beyond the chest; BF, progressive disease in a previously existing site or a new site of metastatic disease in the brain, with no evidence of extracranial progression; OF, progressive disease in other distant sites or multiple sites including the chest and intracranial region. T790M mutation was detected by ddPCR

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us